Curevo Vaccine
curevovaccine.com
Biotechnology
Vaccines
Infectious Disease Therapeutics
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Backers
1
OrbiMed
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
OrbiMed Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene modulation therapy utilizing…
Genvax Technologies is an animal vaccine company developing next-generation mRNA + nanoparticle vaccines from Ames, Iowa. Our mission is to…
Protecting Our Future. ReNewVax is a next-generation bacterial vaccine company developing the first universal vaccine targeting all ca.100…
Gamgee is developing personalised mRNA vaccines as a cancer treatment for dogs, built from each dog’s tumour. See how it works with vets…
Clinical Phase 2 Study - BE RESPONDER!. Cytuvax has completed the Phase 2 BE RESPONDER! clinical study to investigate the immunogenicity…
Ottimo Pharma is an innovative, clinical-stage, biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies to extend…
News
GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine
GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shingles vacc
Read more
Report
Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced it has been
Read more
Report
Report